Astorg, a leading European private equity firm, signed a binding agreement to acquire CordenPharma group (“CordenPharma”), a global leading pharmaceutical Contract Development & Manufacturing Organization with highly differentiated capabilities in Active Pharmaceutical Ingredients, Excipients, and Drug Products, from ICIG. Milbank LLP advised the management of CordenPharma comprehensively in connection with the transaction and in particular with respect to the management participation.
Established in 2006, CordenPharma today employs more than 2,600 people in 11 manufacturing facilities and one R&D laboratory located across Europe and the United States. CordenPharma serves more than 250 blue-chip pharma and biotech customers across five technology platforms: Peptides, Lipids & Carbohydrates (notably lipids for mRNA vaccines and therapeutics), Highly Potent & Oncology, Injectables and Small Molecules. As a key partner for the pharma industry, CordenPharma provides distinctive know-how, an integrated product offering and end-to-end capabilities from early-stage development to commercial large-scale manufacturing.
The Milbank team was led by partners Michael Bernhardt (Corporate/M&A, Frankfurt) and Matthias Schell (Tax, Munich) and included associates Sarah-Maria Resch (Corporate/M&A, Frankfurt) and Arne Hammerich (Tax, Munich).
